Clinical Trials
27 trialsInduction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI)
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI)
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
National Cancer Institute (NCI)
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
National Cancer Institute (NCI)
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
National Cancer Institute (NCI)
Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer
National Cancer Institute (NCI)
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)
Brachytherapy in Treating Patients With Recurrent Prostate Cancer
National Cancer Institute (NCI)
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
National Cancer Institute (NCI)
Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
National Cancer Institute (NCI)
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
National Cancer Institute (NCI)
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Cervical Cancer
National Cancer Institute (NCI)
Epoetin Beta in Treating Anemia in Patients With Cervical Cancer
National Cancer Institute (NCI)
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
National Cancer Institute (NCI)
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer
National Cancer Institute (NCI)
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
National Cancer Institute (NCI)
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Collaborative Ocular Melanoma Study (COMS)
National Eye Institute (NEI)